M&A Deal Summary |
|
|---|---|
| Date | 2024-07-18 |
| Target | PacBio - Revio Sequencing System |
| Sector | Life Science |
| Buyer(s) | Medgenome |
| Sellers(s) | Pacific Biosciences of California |
| Deal Type | Divestiture |
SEARCH BY
Medgenome is a genomics-driven research and diagnostics company. Medgenome was founded in 2013 and is based in Bangalore, Karnataka.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 2 of 2 |
| Year: 2024 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-02-24 |
Lifecode
Foster City, California, United States Lifecode, Inc. is a personalized medicine company. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2004 |
| Sector | Life Science |
Pacific Biosciences of California, Inc. offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2024 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-08-02 |
Apton
Pleasanton, California, United States Apton is a developer of Super-Res™ sequencing and single-molecule detection systems for large-scale clinical applications such as early cancer detection and population sequencing. Apton has re-imagined the optical systems for sequencing using super-resolution to evaluate molecules spaced closer than a wavelength of light. Apton's Super-Res™ technology sequences tens of billions of reads in a single run using simple, un-patterned flow cells that lower variable costs. Apton was founded in 2012 and is based in Pleasanton, California. |
Buy | $110M |
